JPMorgan Chase & Co. Increases BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00

BioCryst Pharmaceuticals (NASDAQ:BCRX - Free Report) had its price target boosted by JPMorgan Chase & Co. from $10.00 to $13.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the biotechnology company's stock.

A number of other equities analysts have also weighed in on BCRX. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $11.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, April 11th. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Needham & Company LLC upped their target price on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $16.56.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded up $0.06 during trading hours on Tuesday, reaching $9.98. 7,606,302 shares of the company traded hands, compared to its average volume of 2,989,382. The firm has a 50-day moving average price of $7.87 and a 200 day moving average price of $7.89. The company has a market cap of $2.09 billion, a P/E ratio of -16.36 and a beta of 1.08. BioCryst Pharmaceuticals has a 12-month low of $5.34 and a 12-month high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same period in the prior year, the firm posted $0.28 EPS. BioCryst Pharmaceuticals's revenue for the quarter was up 40.8% on a year-over-year basis. Sell-side analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. raised its stake in shares of BioCryst Pharmaceuticals by 177.8% in the third quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company's stock valued at $1,968,000 after acquiring an additional 168,790 shares during the period. KBC Group NV grew its stake in shares of BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after buying an additional 4,537 shares during the last quarter. R Squared Ltd purchased a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth approximately $48,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 43,920 shares of the biotechnology company's stock worth $330,000 after acquiring an additional 4,129 shares during the last quarter. Finally, Choreo LLC purchased a new position in BioCryst Pharmaceuticals during the 4th quarter valued at $106,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.